Top NYC, NY Biotech Companies (114)
Kingdom designs and supplies Superculture™ ingredients that make it easy for food and beverage manufacturers to create products that are healthier, more natural, and more sustainable. Our vision is to replace artificial chemicals and genetically-modified organisms with natural Superculture™ ingredients as the backbone of the modern CPG industry.
The PathSpot System protects your business by scanning hands to detect harmful contaminants that cause common illness.
UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities
At PathAI our mission is to improve patient outcomes with AI-powered technology. PathAI’s platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine and deep learning.
We are an international biotech company committed to improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, our passionate, innovative, and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, we have formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotech company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions, and execute; feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinary experience. Established in 1999, we are headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S., and Tokyo, Japan. For more information, please visit Genmab.com Disclaimer: http://bit.ly/GENDisclaimer
Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 300,000 customers from over 160 countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript currently has over 5,000 employees globally, 33% holding master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 100 patents and over 270 patent applications. As of June 2022, GenScript's products and services have been cited by 74,700 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.
Meet IFF: We boldly bring together science and creativity to create what the world needs. An industry leader in food, beverage, health and biosciences, we create essential solutions – from global icons to unexpected innovations and experiences. Equal parts outspoken and analytical, our international collective of thinkers working with customers to bring scents, tastes, experiences, ingredients and solutions for products people crave. With 24,000 employees across 65 countries, more than 110 manufacturing facilities, 100 R&D centers, and 33,000 customers across the world, we’re poised to make a difference on an unprecedented scale. Without our boundary-pushing passion and end-to-end expertise, the future wouldn’t be the same. Visit us at www.iff.com to learn more about how our talented people and new technology are challenging the expected, championing creators and doing more good for people and planet. Explore what sets us apart.
Kinevant Sciences is a clinical-stage biopharmaceutical company dedicated to treating rare autoimmune diseases with significant unmet need. Our lead candidate, namilumab, is an investigational monoclonal antibody being developed for the treatment of sarcoidosis. Namilumab targets GM-CSF, a key pro-inflammatory cytokine and growth factor implicating in the pathogenesis of sarcoidosis and other inflammatory disorders. We plan to initiate a global Phase 2 clinical trial in the first half of 2022 investigating namilumab in pulmonary sarcoidosis, which affects ~90% of all sarcoidosis patients.
Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases. Our purpose is to accelerate treatments and fundamentally improve mental health.
LifeLens was founded in 2014 by Dr. Robert Schwartz, Landy Toth, David Robins, and Dr. Robert Van Tassel. Its mission is to create simple, commercially viable technologies for high fidelity physiologic monitoring.
Pulse Analytics builds business intelligence tools that help decision-makers in oncology and other specialty therapeutic areas reduce access barriers and restrictions in the healthcare industry. Pharma market access teams utilize our tools to understand the complex connections, policies, and key influencers at healthcare organizations to deliver targeted insights and support their customer engagement strategies. We go above traditional data platforms by operating in a highly specialized space and partnering with industry experts allowing our tools to provide tailored experiences that meet the unique needs and challenges of our clients.
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai
With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, MedTech, and Pharma Services. ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds, including the largest healthcare-only private equity fund raised by a European-based General Partner. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation.
Code Ocean is where great computational research is created, organized, and shared in one place. It is the best way for research teams to standardize research workflow, plus track and reproduce all computations and discoveries. Research and development organizations benefit from lower IT costs, automation to operationalize reproducibility, and saving wasted researcher and collaboration time. Our mission is to make computational research a connected community that together drives for faster, more collaborative, higher quality discoveries. For the first time, researchers, engineers, developers and scientists can track and share reproducible code, data, results, and a working computational environment with the associated article and project. We assign a Digital Object Identifier (DOI) to the algorithm allowing for correct attribution and connect it to the published research.
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.
Celmatix is a next-generation women’s health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions. Since its foundation in 2009, Celmatix has been committed to empowering women with genetic insights about their fertility and reproductive health.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our U.S. manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.
Evvy is a female-founded startup building a new understanding of the female body. Our at-home vaginal microbiome test is the first to leverage metagenomic sequencing to help anyone with a vagina understand what’s up down there, why it matters, and what they can do about it. Why the vaginal microbiome? Turns out, at least 30% of people with vaginas suffer from imbalances in the vaginal microbiome every year (read: bacterial vaginosis, yeast infections, and UTIs). What’s more — the latest research has uncovered groundbreaking links between the vaginal microbiome and infertility, STIs, preterm birth, gynecologic cancers, and more. But even though the vaginal microbiome is an important biomarker, women and people with vaginas have never had access to that information about their own bodies — until now.
EncrypGen makes next-generation software to aide in safely storing and sharing genomic data for research and science, and to allow users to manage their own data and sell it to researchers.
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.
